ETHZilla PEG

Mitä ETHZilla tekee? 180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases, focusing on three research programs: Fibrosis and Anti-TNF, SCAs, and a7nAChR. The Fibrosis and Anti-TNF program targets conditions such as Dupuytren’s contracture, frozen shoulder, polycystic ovarian disease (POCD), and nonalcoholic steatohepatitis (NASH). The SCAs program addresses chronic pain and early arthritis, while the a7nAChR program focuses on smoking cessation and ulcerative colitis. The company generates revenue through the development and potential future sale of these pharmaceutical products, targeting patients and healthcare providers in the treatment of inflammatory and chronic pain conditions. The company operates as a research and development firm with a pipeline of drugs in separate areas of inflammation. Its products are designed to treat specific diseases within inflammation, including Dupuytren’s contracture, frozen shoulder, POCD, NASH, chronic pain, early arthritis, and ulcerative colitis. Revenue is derived from the commercialization of these pharmaceuticals once they reach the market, with no mention of current sales or partnerships in the business description. 180 Life Sciences Corp. is structured around three distinct drug development programs, each targeting a specific disease area. The Fibrosis and Anti-TNF program covers multiple inflammatory conditions, while SCAs and a7nAChR address chronic pain and smoking-related health issues, respectively. The company’s revenue model relies on the successful development and market entry of these pharmaceuticals, with no indication of current revenue streams beyond its R&D phase. ETHZilla on yksi Eurpooliin suosituimmista yhtiöistä.